


**Product Name** : HRX-0233  
**Cat. No.** : PC-21799  
**CAS No.** : 2409140-12-9  
**Molecular Formula** : C<sub>24</sub>H<sub>21</sub>F<sub>2</sub>N<sub>5</sub>O<sub>3</sub>S  
**Molecular Weight** : 497.52  
**Target** : MEK (MAP2K)  
**Solubility** : 10 mM in DMSO



CAS: 2409140-12-9

### Biological Activity

HRX-0233 (HRX0233) is a potent, selective **MAP2K4 (MKK4)** inhibitor, HRX-0233 is synergistic with RAS inhibitors in KRAS-mutant cancers.

Combination of sotorasib, a drug targeting KRASG12C, and the MAP2K4 inhibitor HRX-0233 prevents this feedback activation and is highly synergistic in a panel of KRASG12C-mutant lung and colon cancer cells.

Combining HRX-0233 and sotorasib is well-tolerated and resulted in durable tumor shrinkage in mouse xenografts of human lung cancer cells.

HRX-0233 combined with MEK inhibition suppresses tumor growth without toxicity in a H2122 xenograft model.

### References

Robin A Jansen, et al. *Proc Natl Acad Sci U S A*. 2024 Feb 27;121(9):e2319492121.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com